The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
One-year outcomes of transcatheter tricuspid valve repair with the Mistral device
Kerstin Piayda1, MD, MSc; Stefan Bertog1, MD; Judith Steffan1, MD; Pamela Ilioska-Damköhler1, MD; Ronen Beeri2, MD; Kolja Sievert1, MD; Horst Sievert1, MD; Ira Yaron3, BSc; Haim D. Danenberg4, MD
1. CardioVascular Center Frankfurt (CVC), Frankfurt, Germany; 2. Department of Cardiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; 3. Mitralix Ltd., Tel-Aviv, Israel; 4. Interventional Cardiology, E. Wolfson Medical Center, Jerusalem, Israel
Transcatheter tricuspid valve intervention (TTVI) has become a valuable treatment option and may be considered in inoperable patients with severe symptomatic tricuspid regurgitation (TR) and a suitable anatomy in whom improvement can be expected1. We present the long-term clinical outcomes of the Mistral device (Mitralix Ltd.), which is used to treat patients with severe functional TR.
The Mistral device is a helix-shaped nitinol wire and allows, in the ideal case, the approximation of all three tricuspid leaflets with one single implant through the inward pulling of the chordae tendineae and subsequent leaflet coaptation. The placement of more than one ...